Back to Journals » Drug Design, Development and Therapy » Volume 11

Ten years of biosimilars in Europe: development and evolution of the regulatory pathways

Authors Schiestl M, Zabransky M, Sörgel F

Received 15 December 2016

Accepted for publication 21 February 2017

Published 16 May 2017 Volume 2017:11 Pages 1509—1515

DOI https://doi.org/10.2147/DDDT.S130318

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Rasika Samarasinghe

Peer reviewer comments 4

Editor who approved publication: Dr Anastasios Lymperopoulos

Martin Schiestl,1 Markus Zabransky,2 Fritz Sörgel3,4

1Sandoz GmbH, Kundl, Austria; 2Sandoz Biopharmaceuticals, Hexal AG, Holzkirchen, Germany; 3Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany; 4Institute of Pharmacology, Faculty of Medicine, University Duisburg-Essen, Essen, Germany

Abstract: A biosimilar is defined by the European Medicines Agency as a biological medicine that is similar to another biological medicine that has already been authorized for use. A science-based regulatory framework to ensure high-quality biosimilars has been established in Europe since 2005 and is monitored and updated on an ongoing basis. The guiding principle of a biosimilar development program is to establish similarity between the biosimilar and the reference medicine by the best possible means, ensuring that the previously proven safety and efficacy of the reference medicinal product also applies to the biosimilar. Development of a biosimilar is underpinned by state-of-the-art analytical techniques to characterize both reference medicines and biosimilars. The extent and nature of the nonclinical in vivo studies and clinical studies to be performed depend on the level of evidence obtained in the previous step(s), including the robustness of the physicochemical, biological, and nonclinical in vitro data. Extrapolation is an important element of the biosimilarity concept. When biosimilar comparability has been demonstrated in one indication, extrapolation of the data package to other indications of the reference medicine could be acceptable, but needs to be scientifically justified and considered in light of the demonstrated level of sameness by all analytical, nonclinical, and clinical data. The credibility of the scientific basis behind the biosimilar concept, and quality of regulatory decision-making, is demonstrated by the successful approval and clinical use of 20 biosimilar medicines since 2006 when Omnitrope® was the first biosimilar to be approved. The regulatory environment for biosimilars continues to evolve, both in recognition of advances in technology/analytical methods and the availability of new targets for biosimilar development.

Keywords: biosimilars, regulatory pathways, Omnitrope®

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Ten years of clinical experience with biosimilar human growth hormone: a review of safety data

Borrás Pérez MV, Kriström B, Romer T, Walczak M, Höbel N, Zabransky M

Drug Design, Development and Therapy 2017, 11:1497-1503

Published Date: 16 May 2017

Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data

López-Siguero JP, Pfäffle R, Chanson P, Szalecki M, Höbel N, Zabransky M

Drug Design, Development and Therapy 2017, 11:1489-1495

Published Date: 16 May 2017